Stocktoria
VYNE Therapeutics Inc. VYNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-25
VYNE Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 |
| R&D expense | $19.2M | $30.9M | $16.3M | $18.4M | $19.5M |
| SG&A expense | — | — | — | $16.4M | $20.3M |
| Operating income | -$29.7M | -$43.6M | -$29.3M | -$34.3M | -$38.9M |
| Interest expense | — | — | — | $0 | $5.6M |
| Income tax | $4,000 | $4,000 | $0 | $13,000 | -$448,000 |
| Net income | -$26.5M | -$39.8M | -$28.5M | -$23.2M | -$73.3M |
| EPS (diluted) | $-0.62 | $-0.93 | $-2.78 | $-7.28 | $-25.64 |
| Operating cash flow | -$33.1M | -$34.0M | -$25.3M | -$29.2M | -$56.4M |
| Free cash flow | — | — | — | — | -$56.4M |
| Cash & equivalents | $24.0M | $19.9M | $30.6M | $30.9M | $42.2M |
| Inventory | — | — | — | — | $7.3M |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.0M |
| Total liabilities | $2.4M | $14.8M | $8.9M | $9.3M | $18.4M |
| Shareholders' equity | $27.8M | $52.1M | $88.7M | $31.2M | $48.6M |
Source: SEC EDGAR filings · CIK 0001566044 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.